Anavex Life Sciences Corp (AVXL)

[circa1762]

The correctness is not theoretical. I am not talking about perception. I am talking about what is needed to establish a new SOC in Alzheimer's that would be earning billions annually within a few short years. People can do whatever they want in the short term after 11/7, but if the data show this drug on track to provide a significant advantage over donepezil (and far less than 83% and 4x will easily do the trick), selling would be a huge long-term mistake.